Cabozantinib

Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is a small-molecule tyrosine-kinase inhibitor (TKI) of c-Met (HGFR) and VEGFR2, and also inhibits ...

1 story • Updated Oct 20, 2025
Cabozantinib
Health

Kura Oncology Unveils Breakthrough Cancer Therapies at ESMO 2025

5 sources Oct 18, 2025